Predictive Value of Soluble CD146 in Patients With Recurrent Glioblastoma Treated by Bevacizumab
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- correlation between soluble CD146 plasma value and patient response (RANO)
研究概览
简要总结
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent and fails to enhance patients' overall survival. The investigators previously identified one novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma (Joshkon et al. Acta Neuropathol Commun, 2022).
Now, the investigators objective is to prospectively monitor the soluble CD146 value in plasma from patients treated by bevacizumab for recurrent glioblastoma.
The investigators will collect plasma at baseline, before the first bevacizumab administration, before the second administration, at the time of first MRI evaluation and at progression. Plasma CD146 value will be analyzed by ELISA.
The investigators expect to confirm the correlation between soluble CD146 value in plasma and patient response to bevacizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Adult patients with recurrent IDHwt glioblastoma
- •Relapse after standard first line treatment (radio-chemotherapy)
- •Candidate for bevacizumab treatment
- •Able to be monitored by MRI
- •KPS ≥ 60%
- •Written signed consent form
排除标准
- •Pregnancy or breast feeding
- •Life expectancy less than 3 months
- •Bevacizumab in first line treatment
- •Other concomitant life-threatening disease
- •Under legal protection
结局指标
主要结局
correlation between soluble CD146 plasma value and patient response (RANO)
时间窗: first evaluation (2 months)
Soluble CD146 plasma value will be assessed using ELISA. Patient response will be evaluated by MRI and clinical response using the international RANO criteria.
次要结局
未报告次要终点